Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company continues with human trials and reported 3Q2025 financial results that showed good cash balances that should allow testing results to bolster BBLG.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials and reported 3Q2025 financial results that showed good cash balances that should allow testing results to bolster BBLG.

BBLG: Cash on Hand to Fuel Commercialization Drive

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company continues with human trials and reported 2Q2025 financial results that showed good cash balances that should allow testing results to bolster BBLG.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials and reported 2Q2025 financial results that showed good cash balances that should allow testing results to bolster BBLG.

BBLG: Making Major Step Toward Commercialization

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company continues with human trials and is getting funding that will enable the approval process to continue.</li><li>BBLG also filed for a patent that stands to strengthen the company's intellectual portfolio.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials and is getting funding that will enable the approval process to continue.BBLG also filed for a patent that stands to strengthen the company's intellectual portfolio.

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company continues with human trials, and we are looking forward to the initial results and suggest investors consider investing ahead of the result release.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials, and we are looking forward to the initial results and suggest investors consider investing ahead of the result release.

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company released its 1Q2025 financial results that showed good cash, low debt and good cost controls.</li><li>The company continues with human trials, and we are looking forward to the initial results.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company released its 1Q2025 financial results that showed good cash, low debt and good cost controls.The company continues with human trials, and we are looking forward to the initial results.

BBLG: Expense Control Key as Trials Continue

United States

Bone Biologics Corporation operates as a biotechnology company. The Company focuses on bone regeneration in human lumbar spinal fusion using recombinant human protein growth factor. Bone Biologics offers bone repair and regeneration applications in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bone Biologics (BBLG US)

BBLG: Cash on Hand to Fuel Commercialization Drive

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

BBLG: Making Major Step Toward Commercialization

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

BBLG: Making Major Step Toward Commercialization

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

BBLG: Now is the Time to Look at BBLG

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

BBLG: Expense Control Key as Trials Continue

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)